Imagine undergoing heart surgery, only to face a devastating complication: acute kidney injury (AKI). Shockingly, up to half of all cardiac surgery patients experience this life-threatening condition, yet effective preventive measures remain elusive. But a groundbreaking study presented at the 2025 American Society of Nephrology Kidney Week offers a glimmer of hope. Researchers have discovered that a specific class of medications, SGLT2 inhibitors, could significantly reduce the risk of AKI after cardiac surgery.
Here’s the fascinating part: SGLT2 inhibitors, traditionally used to manage diabetes, have shown promise in protecting the kidneys. But here’s where it gets controversial: while these drugs have been linked to better kidney and heart outcomes in previous trials, their role in preventing post-surgical AKI has been less clear—until now. The MERCURI-2 trial, a meticulously designed multicenter study, set out to test whether dapagliflozin, an SGLT2 inhibitor, could shield patients from AKI during the critical perioperative period.
In this triple-blinded, placebo-controlled trial, adult patients scheduled for elective cardiac surgery were randomly assigned to receive either 10 mg of dapagliflozin or a placebo daily, starting the day before surgery and continuing for two days post-operation. The results were striking: the dapagliflozin group saw a 25% absolute reduction in AKI incidence compared to the placebo group (28% vs. 53%, P<0.001). And this is the part most people miss: the benefits extended across all stages of AKI, with significantly fewer patients in the dapagliflozin group progressing to severe kidney injury.
Let’s break down the numbers: In the dapagliflozin group, only 23% of patients developed stage 1 AKI, compared to 40% in the placebo group. Stage 2 AKI was even rarer, affecting just 4% of dapagliflozin patients versus 13% of placebo patients. While stage 3 AKI was uncommon in both groups, the trend still favored dapagliflozin. Could this be the game-changer cardiac surgery patients have been waiting for?
The study’s authors are confident, stating, “This large multicenter trial confirmed that perioperative SGLT2 inhibition can prevent cardiac surgery-associated AKI.” But here’s a thought-provoking question for you: Should SGLT2 inhibitors now be considered standard care for cardiac surgery patients, or are there potential risks and costs we’re not fully considering? Share your thoughts in the comments—this is a conversation worth having. For more details, check out the full study at doi:10.1681/ASN.2025y8v7b58n.
